VBI Vaccines Inc (VBIV)
NASDAQ (CM) NASDAQ (CM) Primary 
TWSE Summary
VBIV Chart
VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (VBI) is initiating a voluntary nationwide recall of all remaining PreHevbrio® [Hepatitis B Vaccine (Recombinant); NDC 75052-001-10] (“PreHevbrio”) due to the bankruptcy of the company and termination of operations. Further distribution or use of any remaining PreHevbrio vaccine by healthcare providers or others must cease immediately. VBI Vaccines Inc. and its affiliates commenced a proceeding under Canada's Companies' Creditors Arrangement.
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI Vaccines (NASDAQ: VBIV ) stock is rising higher on Tuesday after the commercial-stage biopharmaceutical company filed for bankruptcy last week. According to a press release from VBI Vaccines, this bankruptcy filing is part of the company's ongoing restructuring effort.
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients. These data will be presented in a poster session at the 2024 American Society of Clinical Onco.
VBI Vaccines Inc Dividends
| VBIV 2 Apr 2012 | Other | $0.25 Per Share |
| VBIV 12 Jan 2006 | Other | $0.75 Per Share |
| VBIV 18 Dec 2003 | Other | $0.25 Per Share |
VBI Vaccines Inc Earnings
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 25 Jun 2024 Date | | - Cons. EPS | - EPS |
| 27 Mar 2024 Date | | - Cons. EPS | - EPS |
| VBIV 2 Apr 2012 | Other | $0.25 Per Share |
| VBIV 12 Jan 2006 | Other | $0.75 Per Share |
| VBIV 18 Dec 2003 | Other | $0.25 Per Share |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 25 Jun 2024 Date | | - Cons. EPS | - EPS |
| 27 Mar 2024 Date | | - Cons. EPS | - EPS |
VBI Vaccines Inc (VBIV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has VBI Vaccines Inc ever had a stock split?
VBI Vaccines Inc Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jeffery R. Baxter FCMA CEO | NASDAQ (CM) Exchange | 91822J103 Cusip |
| US Country | 131 Employees | 28 Dec 2012 Last Dividend | 12 Apr 2023 Last Split | - IPO Date |
Overview
VBI Vaccines Inc. is a commercial-stage biopharmaceutical entity focused on the development and commercialization of vaccines for immuno-oncology and infectious diseases. Known for its innovative approach to vaccine development, the company has successfully brought to market multiple hepatitis B (HBV) vaccines, including PreHevbrio, PreHevbri, and Sci-B-Vac. Initially named SciVac Therapeutics Inc., the company underwent a rebranding to VBI Vaccines Inc. in May 2016 to better reflect its expanded focus and development portfolio. The company's strategic partnerships with entities such as Brii Biosciences Limited, the National Research Council of Canada, and the Coalition for Epidemic Preparedness Innovations highlight its collaborative approach to vaccine development and its commitment to addressing global health challenges. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. positions itself as a key player in the biopharmaceutical industry with a broadening pipeline of therapeutic and prophylactic vaccine candidates.
Products and Services
- PreHevbrio, PreHevbri, and Sci-B-Vac – These are brand names under which the company's hepatitis B (HBV) vaccines are marketed. Each brand leverages unique formulations and approaches to provide immunity against HBV, a significant global health concern.
- VBI-2601 – A novel protein-based immunotherapeutic candidate that targets chronic HBV infections, aiming to improve patient outcomes by potentially offering a functional cure through immune system modulation.
- VBI-1901 – An experimental immunotherapeutic candidate for the treatment of glioblastoma, one of the most aggressive and lethal forms of brain cancer. VBI-1901 seeks to enhance patient's immune responses against cancer cells.
- VBI-1501 – A vaccine candidate designed as a preventive measure against cytomegalovirus (CMV) infections. By stimulating the immune system to defend against CMV, VBI-1501 could significantly reduce the incidence and impact of this widespread and potentially severe virus.
- VBI-2501 – Developed for the treatment of Zika virus, this vaccine candidate utilizes the company's innovative platform to provide protection against Zika, a virus known for causing severe birth defects during pregnancy and other health complications.
- Coronavirus Vaccine Candidates: VBI-2902, VBI-2901, and VBI-2905 – Representing VBI Vaccines Inc.'s response to the global COVID-19 pandemic, these candidates are in various stages of development and testing. Each candidate reflects the company's committed effort to leverage its technological and scientific expertise to combat coronavirus and its variants.
Contact Information
